Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sana Biotechnology, Inc.SANA · Entity 4870 | EVP, Chief Financial Officer | March 07, 2024 | March 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sana Biotechnology, Inc.
Report date March 07, 2024 · Filed March 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 67,083 |
Reported balance
After 2024-03-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-07 · Grant · Acquired 67,083 · Balance 67,083 F1: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F2: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.58 · Expires 2034-03-06 | Direct | 301,875 |
Reported balance
After 2024-03-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-07 · Grant · Acquired 301,875 · Balance 301,875 F3: The option vests and becomes exercisable as to 25% of the underlying shares on March 7, 2025 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.
F2: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
F3: The option vests and becomes exercisable as to 25% of the underlying shares on March 7, 2025 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2024 Filed Mar 8, 2024 21:16 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 301,875 | $0.00 Strike: $9.58 | $0.00 |
DisclosureSEC source: 0001562180-24-002476 · primarydocument.xml · derivative · entry 2 Hardy Nathan · CIK 0001830053 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 301,875 Underlying: Common Stock · 301,875 shares Expires 2034-03-06 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 7, 2025 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 21:16 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantRestricted Stock Units · Derivative | 67,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-002476 · primarydocument.xml · derivative · entry 1 Hardy Nathan · CIK 0001830053 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,083 Underlying: Common Stock · 67,083 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. F2 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document |
| November 02, 2023 Filed Nov 3, 2023 20:07 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-007547 · primarydocument.xml · derivative · entry 1 Hardy Nathan · CIK 0001830053 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F2 · derivative.exercise_date: The restricted stock units will vest in full on January 2, 2025, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date. F2 · derivative.expiration_date: The restricted stock units will vest in full on January 2, 2025, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:34 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Options (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-23-002395 · primarydocument.xml · derivative · entry 1 Hardy Nathan · CIK 0001830053 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-03-01 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 2, 2024 and in 36 equal monthly installments thereafter. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 14:03 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Options (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0001562180-22-002425 · primarydocument.xml · derivative · entry 1 Hardy Nathan · CIK 0001830053 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2032-03-02 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 3, 2023 and in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.